{"product_id":"angiodynamics-swot-analysis","title":"AngioDynamics SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAngioDynamics shows strong niche leadership in minimally invasive vascular devices, but faces pricing pressure, patent expiries, and competitive innovation risks. Our full SWOT decodes these dynamics, quantifies financial implications, and pinpoints strategic moves for growth. Purchase the complete, editable SWOT to turn insights into actionable decisions for investors and executives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiverse minimally invasive portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAngioDynamics’ diverse minimally invasive portfolio spans angioplasty, thrombolysis and embolization, serving vascular and oncologic use-cases and helping smooth revenue across hospitals and ASCs; 2024 revenue was about $484 million. This breadth enables effective cross-selling to existing hospital and ASC customers and supports recurring consumable sales. A multi-therapy footprint reduces exposure to single-product volatility and aids resilience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFocus on interventional specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAngioDynamics (NASDAQ: ANGO) is deeply embedded with interventional radiologists and vascular surgeons who drive minimally invasive adoption; close clinician ties enable feedback-driven innovation and procedural training, accelerating uptake of new devices and strengthening a defensible specialist niche versus generalist competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology and vascular disease expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAngioDynamics' strength in peripheral vascular disease and interventional oncology taps large, expanding markets—market reports forecast peripheral vascular devices to grow ~6% CAGR and interventional oncology ~7% CAGR through 2030—driven by aging populations and rising procedure volumes. Organ-sparing ablation and embolization fit clinical shifts toward less invasive care, supporting premium pricing backed by clinical evidence and offering procedure growth less tied to hospital capital cycles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecurring disposables revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMany AngioDynamics products are single-use or include consumable components, creating repeatable demand tied directly to procedure volumes.\u003c\/p\u003e\n\u003cp\u003eThat recurring disposables revenue provides cash-flow visibility and steadier gross margins compared with lumpy capital equipment sales.\u003c\/p\u003e\n\u003cp\u003eHigher utilization of disposables can scale revenue without proportional SG\u0026amp;A increases, improving operating leverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeatable demand from single-use devices\u003c\/li\u003e\n\u003cli\u003eImproves cash-flow predictability\u003c\/li\u003e\n\u003cli\u003eStabilizes margins vs. capital sales\u003c\/li\u003e\n\u003cli\u003eScales with utilization without large SG\u0026amp;A growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory know-how and market access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAngioDynamics leverages deep regulatory know-how—its long history of FDA clearances has enabled steady incremental innovation and faster 510(k)\/PMA pathways, supporting a reported 2024 revenue of $596 million and ongoing line extensions.\u003c\/p\u003e\n\u003cp\u003eEstablished GPO and institutional contracts (including Vizient and Premier) ensure broad distribution and lower barriers to market for new variants and adjacencies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory track record › speeds approvals\u003c\/li\u003e\n\u003cli\u003e2024 revenue › $596M\u003c\/li\u003e\n\u003cli\u003eGPO access › broad distribution\u003c\/li\u003e\n\u003cli\u003eFoundation › eases line extensions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumable-led min invasive portfolio: 2024 rev \u003cstrong\u003e596M\u003c\/strong\u003e, CAGR \u003cstrong\u003e6–7%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAngioDynamics' diversified minimally invasive portfolio and consumable-heavy model drove recurring revenue and operating leverage; reported 2024 revenue 596M. Strong clinician relationships and GPO contracts aid cross-selling and rapid adoption. Focused exposure to peripheral vascular and interventional oncology targets growing markets (~6–7% CAGR).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e596M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumable mix\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket CAGR\u003c\/td\u003e\n\u003ctd\u003e6–7% through 2030\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT analysis of AngioDynamics, highlighting its core strengths, internal weaknesses, market opportunities, and external threats to assess the company’s strategic positioning and growth prospects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT matrix of AngioDynamics to quickly surface strengths, weaknesses, opportunities and threats, simplifying strategic decisions and stakeholder communication. Editable format supports rapid updates to reflect changing market conditions for fast, actionable planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmaller scale vs major medtechs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompared with giants like Medtronic (FY2024 revenue ~$33.8B) and Boston Scientific (~$12.7B), AngioDynamics operates at a much smaller scale—revenues under $1B—limiting R\u0026amp;D, marketing and manufacturing reach and constraining pricing power and hospital share-of-voice. Larger rivals can outspend on clinical trials and global sales coverage, capturing incremental hospital contracts. Scale disadvantages also drive higher per-unit costs, pressuring margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct concentration risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReliance on a limited set of therapy categories heightens AngioDynamics exposure to shifts in clinical guidelines, making revenue sensitive to changes in physician preference. If a key device faces safety concerns or competitive displacement, the revenue impact can be material given concentrated end-market drivers. Broad SKU counts may mask underlying category concentration, and portfolio pruning can create transitional revenue gaps as replacement sales ramp.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement sensitivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProcedure volumes for AngioDynamics hinge on favorable CPT coding and payer policies; Medicare and large commercial insurers drive the bulk of vascular procedure reimbursements, and changes can quickly reduce demand. Reimbursement cuts and site-of-care shifts toward lower-paid ASCs or clinics compress margins and slow device adoption. Smaller firms like AngioDynamics have less lobbying power than major medtech peers to influence coverage decisions. Geographic variability in payer mixes complicates coherent national pricing and grew more pronounced during 2023–2024 reimbursement updates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic mix skewed to U.S.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAngioDynamics' revenue remains heavily U.S.-weighted, with North America representing roughly three-quarters of net sales in FY2024, which can constrain growth if domestic demand slows and concentrates regulatory and payer exposure. International sales are under-penetrated, leaving substantial addressable market unrealized, but scaling global channels will require significant capex and time. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eU.S. concentration ≈ 75% (FY2024)\u003c\/li\u003e\n\u003cli\u003eLimits growth if domestic demand softens\u003c\/li\u003e\n\u003cli\u003eHeightened regulatory\/payer risk\u003c\/li\u003e\n\u003cli\u003eGlobal expansion needs investment\/time\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality, recall, and supply complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSingle-use sterile devices require near-zero defect rates; recalls erode AngioDynamics brand and margins and invite heightened FDA scrutiny and remediation costs in 2024–25.\u003c\/p\u003e\n\u003cp\u003eReliance on multi-vendor components increases supply-chain fragility and smaller inventories amplify stock-out impacts on procedure volumes and customer trust.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory exposure: higher remediation costs\u003c\/li\u003e\n\u003cli\u003eRecall risk: brand and financial damage\u003c\/li\u003e\n\u003cli\u003eSupply complexity: multi-vendor dependencies\u003c\/li\u003e\n\u003cli\u003eInventory trade-off: stock-out vs. carrying cost\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScale gap vs Medtronic\/Boston Scientific — FY2024 revenue under \u003cstrong\u003e$1B\u003c\/strong\u003e, U.S. \u003cstrong\u003e≈75%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eScale is small versus Medtronic (FY2024 rev ~$33.8B) and Boston Scientific (~$12.7B), limiting R\u0026amp;D, sales reach and pricing power; FY2024 revenue \u0026lt; $1B. Revenue concentration in a few therapy categories and reliance on CPT\/reimbursement expose results to guideline or payer shifts. U.S. weighting (~75% of FY2024 sales) plus supply, recall and regulatory risks magnify downside.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (FY2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAngioDynamics revenue\u003c\/td\u003e\n\u003ctd\u003e\u0026lt; $1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. share\u003c\/td\u003e\n\u003ctd\u003e≈75%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedtronic revenue\u003c\/td\u003e\n\u003ctd\u003e$33.8B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBoston Scientific revenue\u003c\/td\u003e\n\u003ctd\u003e$12.7B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eAngioDynamics SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual AngioDynamics SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report you'll get; buy to unlock the complete, editable version. You’re viewing a live excerpt of the final file, structured and ready to use immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eO\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003epportunities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAging population and disease burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRising prevalence of PAD (236 million adults in 2015), chronic venous disease (affecting up to 40% of adults) and cancer (19.3 million new cases in 2020) expands AngioDynamics' addressable market. Minimally invasive therapies align with faster recovery and outpatient care trends. Higher-comorbidity populations favor endovascular options, driving procedure growth and recurring consumables pull-through.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterventional oncology expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBroader adoption of ablation and embolization for liver, kidney, lung and bone metastases is accelerating, with procedure volumes rising in the high single digits annually and interventional oncology procedures now representing a meaningful share of oncology care pathways. New indications and combo regimens with systemic therapies (immuno\/targeted agents) can expand usage and payer interest. Robust evidence generation can secure guideline inclusion and reimbursement, while bundled tumor-care solutions could drive share gains for AngioDynamics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational and ASC growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEmerging markets and ex-US regions show underpenetrated demand for cost-effective vascular and oncology devices, with medtech growth in emerging markets projected at roughly 6–8% CAGR through 2026 (IQVIA). Ambulatory surgery centers have increased vascular\/oncology case mix, favoring disposable-driven models and higher per-case consumable use. Tailored pricing and local distribution partnerships can unlock volume; AngioDynamics reported roughly 25% of sales from international markets in FY2024, highlighting runway for expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePortfolio adjacencies and innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExtensions into drug-delivery, venous interventions, AV access and imaging-guided tools can leverage AngioDynamics’ clinical call points to access growing segments; smart catheters and data-enabled devices add differentiation and enable premium pricing supported by clinical outcomes. Iterative product improvements can win hospital tenders without full redesigns, while robust clinical evidence supports higher-tier placement and reimbursement.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdjacency focus: drug-delivery, venous, AV access, imaging\u003c\/li\u003e\n\u003cli\u003eDifferentiation: smart catheters, data-enabled devices\u003c\/li\u003e\n\u003cli\u003eGo-to-market: iterative upgrades to win tenders\u003c\/li\u003e\n\u003cli\u003eValue capture: clinical evidence → premium tiers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic partnerships and M\u0026amp;A\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eStrategic partnerships with hospitals, OEMs, and pharma can accelerate clinical trials and market access while co-development deals lower R\u0026amp;D risk and shorten time-to-revenue for AngioDynamics.\u003c\/p\u003e\n\u003cp\u003eTargeted acquisitions can fill capability gaps and add scale in key geographies or product categories, and successful integration expands GPO coverage and contracting leverage.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCollaborations: accelerate trials\/market access\u003c\/li\u003e\n\u003cli\u003eCo-development: reduces R\u0026amp;D risk\/time-to-revenue\u003c\/li\u003e\n\u003cli\u003eM\u0026amp;A: fills gaps, adds geographic\/product scale\u003c\/li\u003e\n\u003cli\u003eIntegration: broadens GPO coverage, boosts contracting leverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Sun-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePAD \u003cstrong\u003e236M\u003c\/strong\u003e, cancer \u003cstrong\u003e19.3M\u003c\/strong\u003e and \u003cstrong\u003e25%\u003c\/strong\u003e intl sales expand market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGrowing PAD (236 million adults in 2015), chronic venous disease (up to 40% adults) and cancer (19.3 million new cases in 2020) expand addressable market; ambulatory shift and high-single-digit IO procedure growth boost consumable pull-through, with ~25% of AngioDynamics sales from international markets in FY2024. Adjacencies, smart\/devices, partnerships and targeted M\u0026amp;A can capture share.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePAD prevalence (2015)\u003c\/td\u003e\n\u003ctd\u003e236M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCancer incidence (2020)\u003c\/td\u003e\n\u003ctd\u003e19.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedtech EM CAGR to 2026 (IQVIA)\u003c\/td\u003e\n\u003ctd\u003e6–8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAngioDynamics FY2024 Intl sales\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterventional oncology growth\u003c\/td\u003e\n\u003ctd\u003eHigh single digits\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eT\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehreats\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntense competition and pricing pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge medtech incumbents and niche innovators increasingly contest AngioDynamics' procedural spaces; AngioDynamics reported roughly $600 million in revenue in 2024, highlighting stakes in core markets. Hospital purchasing groups and GPOs drive commoditization—discounts commonly exceed 20–30%—pressuring prices on staples like balloons and catheters. Sustained price cuts can erode gross margins, so product differentiation must be continually refreshed to defend share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and compliance headwinds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTighter FDA expectations and the EU MDR, which came into full effect on May 26, 2021, increase approval costs and timelines for AngioDynamics, with heightened post-market surveillance obligations and periodic safety update reporting. Rising surveillance burdens and extended reviews can delay launches and cede first-mover advantage in fast-moving vascular device segments. Noncompliance risks include regulatory fines, warning letters, and product withdrawals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLitigation and product liability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInvasive vascular devices carry inherent adverse-event risks, and product-liability suits can impose significant legal costs and reputational harm for AngioDynamics. Insurance programs may not fully cover multi-million-dollar claims, exposing equity and cash flow. Prolonged litigation diverts management time, increases defense expenses, and can slow R\u0026amp;D and product launches, impacting competitive position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply chain and component shortages\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDependence on specialized materials and limited sterilization capacity creates production bottlenecks for AngioDynamics, raising costs of goods sold and risking unmet demand and lost sales.\u003c\/p\u003e\n\u003cp\u003eGeopolitical shocks and transport disruptions constrain logistics and sourcing; qualifying alternate suppliers under FDA\/ISO requirements typically takes months, delaying recovery of supply continuity.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eMaterial\/sterilization bottlenecks\u003c\/li\u003e\n\u003cli\u003eHigher COGS, risk of lost sales\u003c\/li\u003e\n\u003cli\u003eGeopolitical logistics risk\u003c\/li\u003e\n\u003cli\u003eSupplier qualification delays (months)\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroeconomic and hospital budget constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTight capital and operating budgets are constraining procedure throughput and slowing adoption of AngioDynamics products, while persistent staffing shortages increasingly defer elective interventions and lengthen sales cycles. Currency swings continue to compress ex-U.S. pricing and input costs, and recessionary shifts in 2024 have altered case mix and payer dynamics toward lower-margin procedures.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReduced procedure volumes\u003c\/li\u003e\n\u003cli\u003eDeferred elective interventions\u003c\/li\u003e\n\u003cli\u003eFX pressure on ex-U.S. margins\u003c\/li\u003e\n\u003cli\u003eRecession-driven payer\/case-mix shifts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Storm-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMed-device margins squeezed by GPO discounts \u003cstrong\u003e20–30%\u003c\/strong\u003e, regulatory delays and supply shocks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAngioDynamics faces margin pressure from GPO-driven discounts (20–30%) and intensified competition despite ~$600M revenue in 2024. Regulatory tightening (FDA\/EU MDR) raises approval costs and delays launches. Supply-chain bottlenecks and geopolitical\/logistics shocks risk lost sales and higher COGS.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eThreat\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003cth\u003e2024\/25 Data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO pricing\u003c\/td\u003e\n\u003ctd\u003eMargin erosion\u003c\/td\u003e\n\u003ctd\u003e20–30% typical discounts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003eLonger time-to-market\u003c\/td\u003e\n\u003ctd\u003eEU MDR active; higher PM surveillance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply\u003c\/td\u003e\n\u003ctd\u003eLost sales, ↑COGS\u003c\/td\u003e\n\u003ctd\u003eSterilization\/material constraints, months to qualify suppliers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58097802019164,"sku":"angiodynamics-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/angiodynamics-swot-analysis.png?v=1781788252","url":"https:\/\/pestel-analysis.com\/products\/angiodynamics-swot-analysis","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}